

Frederick R Ueland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7761901/publications.pdf>

Version: 2024-02-01

46
papers

998
citations

623574

14
h-index

454834

30
g-index

46
all docs

46
docs citations

46
times ranked

1170
citing authors

#	ARTICLE	IF	CITATIONS
1	Significance of Pelvic Fluid Observed during Ovarian Cancer Screening with Transvaginal Sonogram. <i>Diagnostics</i> , 2022, 12, 144.	1.3	1
2	Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type. <i>Diagnostics</i> , 2022, 12, 128.	1.3	4
3	Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy. <i>Cancers</i> , 2022, 14, 2220.	1.7	30
4	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€“MONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964.	0.8	125
5	Clinicopathological effects of body composition measurements for patients with endometrial cancer. <i>Minerva Ginecologica</i> , 2021, 72, 430-435.	0.8	0
6	Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment. <i>Diagnostics</i> , 2021, 11, 395.	1.3	11
7	Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative. <i>Diagnostics</i> , 2021, 11, 1440.	1.3	14
8	Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance. <i>Biomedicines</i> , 2021, 9, 1021.	1.4	13
9	Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0254205.	1.1	9
10	Real-World Evaluation of Universal Germline Screening for Cancer Treatment-Relevant Pharmacogenes. <i>Cancers</i> , 2021, 13, 4524.	1.7	6
11	Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer. <i>Biomedicines</i> , 2021, 9, 70.	1.4	7
12	Characterization of Uterine Cervix Cancers in Women from Appalachian Kentucky. <i>Frontiers in Oncology</i> , 2021, 11, 808081.	1.3	2
13	Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky. <i>Journal of Rural Health</i> , 2020, , .	1.6	3
14	CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer. <i>Diagnostics</i> , 2020, 10, 279.	1.3	59
15	Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells. <i>Diagnostics</i> , 2020, 10, 121.	1.3	30
16	Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancersâ€“Stage Challenges Categorical Assignments of Indolence & Aggressiveness. <i>Diagnostics</i> , 2020, 10, 56.	1.3	11
17	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. <i>PLoS ONE</i> , 2020, 15, e0244558.	1.1	10
18	Uterine Corpus Malignancies in Appalachia Kentucky: Incidence, Survival, and Related Health Disparities. <i>Southern Medical Journal</i> , 2020, 113, 29-36.	0.3	2

#	ARTICLE	IF	CITATIONS
19	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
20	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
21	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
22	DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. , 2020, 15, e0244558.		0
23	Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery. Healthcare (Switzerland), 2019, 7, 85.	1.0	8
24	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	0.6	16
25	Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years. Surgical Oncology, 2019, 29, 25-32.	0.8	1
26	Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecologic Oncology, 2018, 148, 267-274.	0.6	14
27	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2018, 149, 525-530.	0.6	24
28	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. Journal of Surgical Oncology, 2018, 117, 488-496.	0.8	15
29	Clinical utility of CA-125 in the management of uterine carcinosarcoma. Journal of Gynecologic Oncology, 2018, 29, e88.	1.0	4
30	Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening. Obstetrics and Gynecology, 2018, 132, 1091-1100.	1.2	25
31	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. Surgical Oncology, 2018, 27, 433-440.	0.8	12
32	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. Annals of Surgical Oncology, 2018, 25, 2756-2766.	0.7	5
33	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. Annals of Surgical Oncology, 2018, 25, 3676-3684.	0.7	14
34	Population-Based Analysis of Patient Age and Other Disparities in the Treatment of Ovarian Cancer in Central Appalachia and Kentucky. Southern Medical Journal, 2018, 111, 333-341.	0.3	5
35	First International Consensus Report on Adnexal Masses: Management Recommendations. Journal of Ultrasound in Medicine, 2017, 36, 849-863.	0.8	72
36	Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecologic Oncology, 2017, 145, 78-87.	0.6	31

#	ARTICLE	IF	CITATIONS
37	Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 145, 50-54.	0.6	11
38	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571.	0.6	9
39	Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2014, 2014, 1-6.	0.6	2
40	Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. <i>Gynecologic Oncology</i> , 2014, 135, 8-12.	0.6	29
41	Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 78.e1-78.e9.	0.7	41
42	The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 65.e1-65.e11.	0.7	14
43	Effectiveness of a Multivariate Index Assay in the Preoperative Assessment of Ovarian Tumors. <i>Obstetrics and Gynecology</i> , 2011, 117, 1289-1297.	1.2	202
44	Long-Term Survival of Women With Epithelial Ovarian Cancer Detected by Ultrasonographic Screening. <i>Obstetrics and Gynecology</i> , 2011, 118, 1212-1221.	1.2	102
45	The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database. <i>Journal of Gynecologic Surgery</i> , 0, , .	0.0	1
46	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	4